Influence of angle kappa and angle alpha on visual outcomes after implantation of a nondiffractive extended-depth-of-focus intraocular lens: a prospective observation study Authors: Nuozhou Wu, Yihua Yao, Biting Zhou, Sinan Liu, Yunhui Zhang, Xiaohui Wang Published: 2026 ABSTRACT AbstractBackgroundWhile large angle kappa (chord µ) and angle alpha (chord α) have been reported to adversely affect visual quality with diffractive multifocal intraocular lenses (MIOLs), their impact on the postoperative visual outcomes of nondiffractive extended depth of focus (EDOF) IOLs remains unclear. This study aimed to evaluate the influence of postoperative angle kappa and angle alpha on visual and optical outcomes following implantation of a nondiffractive EDOF IOL.MethodsThis prospective observational study included 115 cataract patients (115 eyes) who underwent implantation of the AcrySof® IQ Vivity® nondiffractive wavefront-shaping EDOF IOL. At 3 months postoperatively, photopic and mesopic angle kappa and angle alpha were measured using the OPD-Scan III. Visual outcomes included uncorrected visual acuity at different distances, objective optical quality parameters, contrast threshold, and patient-reported subjective visual disturbance scores. We performed partial correlation analyses to examine the relationships of angle kappa and angle alpha with postoperative visual outcomes, while controlling for potential confounding variables. Subgroup analyses based on clinically relevant offset thresholds were additionally conducted.ResultsAt 3 months postoperatively, most postoperative angle kappa and angle alpha values were within physiological ranges, with only a small number of eyes having values ≥ 0.5 mm (photopic angle kappa: n = 7; mesopic angle kappa: n = 10; angle alpha: n = 29). Partial correlation analyses demonstrated no significant associations between photopic or mesopic angle kappa and postoperative visual acuity, objective optical quality metrics, or subjective visual disturbance scores (all P > 0.05). Angle alpha showed weak but statistically significant positive correlations with uncorrected distance visual acuity and contrast threshold (P < 0.05), indicating slightly better visual performance with larger angle alpha values. No significant differences in visual outcomes were observed among angle kappa and angle alpha subgroups.ConclusionsWithin the observed postoperative range, angle kappa and angle alpha were not associated with clinically meaningful deterioration in visual performance following implantation of a nondiffractive EDOF IOL. These findings suggest that wavefront-shaping EDOF designs may be tolerant to moderate angular offsets in routine clinical practice.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12886-026-04993-5.Keywords: Extended depth of focus, Non-diffractive intraocular lens, Angle kappa, Angle alpha, Visual quality Background In modern cataract and refractive surgery, there is substantial clinical demand for extended depth-of-focus (EDOF) intraocular lenses (IOLs) that provide a continuous range of functional vision with minimal optical disturbances. Non‑diffractive EDOF IOLs represent a promising technological strategy aimed at achieving this dual goal of broad visual performance and high optical quality. The AcrySof® IQ Vivity® IOL (Alcon), as one of the first commercially available non‑diffractive extended‑depth‑of‑focus lenses, employs a wavefront‑shaping optical principle. Through continuous modulation of the anterior optic surface within a central optical zone, the design elongates the focal range without relying on diffractive light splitting. This approach aims to enhance intermediate and near functional vision while preserving an optical disturbance profile similar to that of a monofocal IOL. Pivotal trials and real-world clinical studies have demonstrated favorable distance and intermediate visual outcomes, with a low incidence of visual disturbances following Vivity implantation [1–3]. In clinical practice, the geometric relationships among the visual axis, optical axis, and pupillary axis may influence the optical performance of an IOL. Two commonly evaluated parameters—angle kappa and angle alpha—have been proposed to modify the distribution of light entering the IOL, thereby potentially affecting both objective optical quality and subjective visual experience, including halos and glare [4, 5]. Angle kappa (frequently reported as chord µ) denotes the linear displacement between the pupil center and the visual axis, whereas angle alpha (chord α) denotes the displacement of the visual axis relative to the corneal vertex (optical axis) [6]. However, evidence regarding the impact of angle kappa and angle alpha on different IOL designs remains inconsistent. Some studies have suggested that when the displacement exceeds a certain threshold (commonly reported at approximately 0.5 mm), multifocal or diffractive IOLs show a significant deterioration in visual quality accompanied by increased photic phenomena [4, 7, 8]. In contrast, several observational studies have found no significant association, or have proposed that postoperative changes in these parameters may weaken their predictive value [9–11]. Selecting an appropriate intraocular lens (IOL) for patients with large angle kappa or angle alpha who desire spectacle independence presents a common and clinically significant challenge in ophthalmic practice. The non-diffractive, wavefront-shaping design of the Vivity IOL offers a potential solution, as it has demonstrated theoretical and in vitro tolerance to moderate angular decentration [12, 13]. Early clinical studies further support its applicability, reporting favorable 3-month functional vision in broad patient cohorts, with outcomes showing no significant association with a range of evaluated preoperative parameters [14]. However, despite these promising optical properties and accumulating clinical evidence demonstrating advantages over diffractive IOLs—including superior contrast sensitivity and a lower incidence of photic phenomena such as glare and halos—high-level prospective evidence remains scarce [1, 2, 15–19]. Specifically, there is a paucity of rigorous data directly correlating postoperative angle kappa and angle alpha with visual performance after Vivity IOL implantation. Consequently, this evidence gap may pose challenges for drawing definitive conclusions regarding its efficacy in patients with significant angular offsets. Therefore, this study aimed to assess the correlations between postoperative angle kappa, angle alpha (measured using the OPD-Scan system) at 3 months following Vivity implantation and a range of optical objective parameters as well as subjective visual outcomes. The goal is to quantify the independent effect of these angular offsets on clinical visual quality and to explore the real-world tolerance of Vivity IOL to angular misalignment. Methods Study design and participants This single-center, prospective observational study consecutively enrolled patients with cataract who underwent implantation of the AcrySof® IQ Vivity® extended depth of focus intraocular lens (EDOF IOL; Alcon Laboratories, Inc.) at the First Affiliated Hospital of Fujian Medical University between July 2024 and September 2025.The study adhered to the tenets of the Declaration of Helsinki and was approved by the ethics committee of the First Affiliated Hospital of Fujian Medical University. Written informed consent was obtained from all participants prior to enrollment. Inclusion criteria were age ≥ 35 years, visually significant cataract requiring surgery, and ability and willingness to attend scheduled follow-up visits. Exclusion criteria comprised corneal pathology, glaucoma, retinal pathology, prior refractive or intraocular surgery, zonular abnormalities, uveitis, amblyopia, and any intraoperative or postoperative complications likely to affect visual outcomes. All patients underwent a standardized preoperative ophthalmic evaluation, including slit-lamp biomicroscopy, uncorrected distance visual acuity (UDVA, logMAR), and non-contact tonometry, optical biometry (IOL Master 700; Carl Zeiss Meditec), corneal topography (Pentacam; Oculus Optikgeräte GmbH), endothelial cell count (SP2000), and fundoscopy to exclude significant posterior segment pathology. Measurement of angle kappa and angle alpha All measurements of angle kappa and angle alpha were obtained using the OPD-Scan III aberrometer (NIDEK Co., Ltd., Japan). Measurements were performed under standardized photopic (85 cd/m²) and mesopic (3 cd/m²) illumination. Angle kappa (chord µ) was defined as the linear distance between the pupillary center and visual axis, and angle alpha (chord α) as the distance between the corneal geometric center and the visual axis (Fig. 1). The OPD-Scan III system reports these parameters as linear offsets (chord µ and chord α) in millimeters on a two-dimensional plane rather than true angular values in degrees; accordingly, the terms “angle kappa” and “angle alpha” are used throughout this manuscript to maintain consistency with clinical nomenclature, although the reported values represent chord-based linear distances. All examinations were conducted by a single experienced examiner. For each eye, three consecutive measurements were obtained under identical conditions, and the mean value was used for subsequent analysis. Corresponding pupil diameters were recorded. Representative OPD-Scan III image demonstrating the automated detection of ocular landmarks and geometric centers. The blue crosshair indicates the visual axial. The green crosshair represents the corneal geometric center (optical axis), derived from the detection of the white-to-white (WTW) boundary (indicated by the green dashed circle). The red and cyan crosshairs indicate the photopic and mesopic pupil centers, respectively IOL power calculation and surgical technique Intraocular lens power was calculated using the Barrett Universal II formula, based on preoperative biometric data and the target refraction. The intended postoperative spherical equivalent ranged from − 0.75 diopters (D) to 0.00 D. For patients with high myopia or specific binocular visual requirements, target refraction was individualized. All surgeries were performed by the same experienced surgeon under topical anesthesia using a standardized phacoemulsification technique. A 2.0 mm clear corneal incision was created along the steep meridian when appropriate. Continuous curvilinear capsulorhexis (approximately 5.5 mm in diameter) was centered on the anterior capsule, followed by phacoemulsification (Stellaris; Bausch & Lomb)and implantation of the Vivity IOL into the capsular bag.Meticulous cortical cleanup and posterior capsule polishing were performed to reduce the risk of posterior capsule opacification. Postoperative medications included levofloxacin(Wanhan Pharmaceutical Co.,China), prednisolone acetate(AbbVie Inc.,USA), pranoprofen(Zhongsheng Pharmaceutical Co.,China) eye drops four times daily, and tobramycin‑dexamethasone ophthalmic ointment(Novartis AG, Switzerland) nightly during the first week, the dosage was tapered once weekly. Postoperative follow-up and clinical measurements Patients were evaluated at 1 week, 1 month, and 3 months postoperatively, the primary endpoint of this study was visual and optical outcomes at 3 months postoperatively. All examinations were performed by a single experienced ophthalmologist to ensure consistency. Clinical assessment included manifest refraction—recording sphere, cylinder, and spherical equivalent (SEQ)—and corrected distance visual acuity (CDVA, logMAR) using a digital phoropter (Huvitz Co., Ltd., Dongtan, South Korea). Uncorrected visual acuity (logMAR) was assessed at multiple distances (5 m, 3 m, 1 m, 60 cm, 40 cm, and 33 cm) using the Binoptometer 4P (Oculus Optikgeräte GmbH, Wetzlar, Germany). Contrast threshold was measured at 3 m with Binoptometer 4P using standard Snellen “E” charts spanning 100% to 2.5% contrast levels; lower (%) values indicate better contrast sensitivity, the lowest identifiable contrast percentage was recorded. At the 3-month visit, objective optical quality parameters and angular characteristics were obtained using the OPD-Scan III. These included the modulation transfer function (MTF) area ratio, Strehl ratio (SR), total and higher-order aberrations (HOAs), as well as angle kappa and angle alpha under both photopic and mesopic conditions. Subjective visual outcomes were assessed using a study-specific questionnaire (provided in the Supplementary Material). This instrument evaluated the frequency and severity of photic phenomena (glare, halos, and starbursts) on a 0–5 scale. Spectacle independence and overall patient satisfaction (0–10 scale) were also recorded. Statistical analysis Continuous variables are presented as mean ± standard deviation, and categorical variables as number and percentage. All statistical tests were two‑sided, with significance set at P < 0.05. Normality was assessed for continuous variables. The prospective design ensured a nearly complete dataset. Missing data were minimal (3.5%) and were assumed to be missing completely at random (MCAR). Given the low proportion of missingness, simple imputation was considered acceptable; continuous variables were imputed using the mean for approximately normally distributed data and the median for skewed distributions. Longitudinal comparisons across follow‑up time points were performed using repeated‑measures analysis of variance or the Friedman test as appropriate, with post‑hoc pairwise comparisons adjusted using the Bonferroni method. Associations between κ and α angles and visual outcomes were examined using Spearman partial correlation, controlling for age, photopic and mesopic pupil diameter and postoperative SEQ. Between‑group comparisons were conducted using the Kruskal–Wallis test (three groups) or the Mann–Whitney U test (two groups). No formal a priori sample size or power calculation was performed, as this study was designed as a prospective observational study with consecutive patient enrollment to reflect real-world clinical practice. All statistical analyses were performed using SPSS version 29.0 (IBM, Armonk, NY, USA). Results Patient baseline characteristics A total of 115 patients (115 eyes) were included in this prospective observational study. Of these, 47 (40.8%) were male and 68 (59.2%) were female. The mean age was 67.16 ± 10.86 years (range, 37–86 years). All enrolled patients completed the 3-month follow-up, and all surgical procedures were completed uneventfully; no sight-threatening intraoperative or postoperative complications occurred. Baseline biometric and clinical parameters are summarized in Table 1. Table 1Baseline characteristics and preoperative angle metricsBaseline dataMean ± SDRangeAge (y)67.16 ± 10.8637, 86Flat keratometry (D)43.39 ± 1.5137.6, 47.1Steep keratometry (D)44.28 ± 1.5938.5, 47.9Corneal astigmatism (D)0.88 ± 0.620, 4.7UDVA (logMAR)0.69 ± 0.300.1, 1.0AL (mm)24.24 ± 1.5521.48, 29.19ACD (mm)3.16 ± 0.392.20, 4.21Corneal endothelial cell count (cell/mm²)2937 ± 3782068, 4043Photopic pupil diameter (mm)3.28 ± 0.542.22, 4.51Mesopic pupil diameter (mm)4.58 ± 0.862.59, 6.93Photopic Angle kappa (mm)0.21 ± 0.120.02, 0.64Mesopic Angle kappa (mm)0.24 ± 0.140.01, 0.65Angle alpha (mm)0.39 ± 0.140.07, 0.86ACD = anterior chamber depth; AL = axial length; logMAR= logarithm minimum angle of resolution; UDVA= uncorrected distance visual acuity Baseline characteristics and preoperative angle metrics ACD = anterior chamber depth; AL = axial length; logMAR= logarithm minimum angle of resolution; UDVA= uncorrected distance visual acuity Postoperative refractive and visual outcomes Table 2 summarizes the postoperative refractive and visual outcomes, with the 3-month visit defined as the primary endpoint. At 3 months, the mean spherical equivalent (SEQ) was − 0.53 ± 0.63 D. Corrected distance visual acuity (CDVA) improved modestly from 0.03 ± 0.07 logMAR at 1 week to 0.01 ± 0.08 logMAR at 3 months (P = 0.001). Uncorrected distance (5 m and 3 m) and intermediate acuities (1 m and 60 cm) improved significantly across visits (all P < 0.001, Friedman test for non-normal variables), whereas uncorrected near acuity (40 cm and 33 cm) remained stable without significant change. Contrast threshold decreased significantly, with the minimum detectable contrast decreasing from 56.82 ± 24.46% at 1 week to 48.91 ± 26.92% at 3 months (P = 0.001). Table 2Postoperative visual and refractive outcomes at 1 week, 1 month, and 3 monthsPostoperative parameterMean ± SD P a 1 week1 month3 monthsSEQ (D)-0.52 ± 0.60-0.40 ± 0.53-0.53 ± 0.63<0.001CDVA (logMAR)0.03 ± 0.070.02 ± 0.060.01 ± 0.080.001UDVA (5 m)0.22 ± 0.130.17 ± 0.110.16 ± 0.12<0.001UDVA (3 m)0.19 ± 0.110.16 ± 0.120.15 ± 0.12<0.001UIVA (1 m)0.15 ± 0.110.13 ± 0.100.13 ± 0.11<0.001UIVA (60 cm)0.17 ± 0.100.16 ± 0.070.15 ± 0.11<0.001UNVA (40 cm)0.26 ± 0.140.26 ± 0.120.24 ± 0.140.302UNVA (33 cm)0.34 ± 0.140.36 ± 0.140.34 ± 0.170.195Contrast Threshold (%)56.82 ± 24.4649.07 ± 22.3548.91 ± 26.920.001a Friedman testSEQ = spherical equivalent; CDVA = corrected distance visual acuity; UDVA = uncorrected distance visual acuity; UIVA = uncorrected intermediate visual acuity; UNVA = uncorrected near visual acuity;Contrast Threshold (%): The minimum contrast percentage required to identify the Snellen “E” optotype at 3 m. A lower value indicates better performance Postoperative visual and refractive outcomes at 1 week, 1 month, and 3 months a Friedman test SEQ = spherical equivalent; CDVA = corrected distance visual acuity; UDVA = uncorrected distance visual acuity; UIVA = uncorrected intermediate visual acuity; UNVA = uncorrected near visual acuity; Contrast Threshold (%): The minimum contrast percentage required to identify the Snellen “E” optotype at 3 m. A lower value indicates better performance Changes in angle kappa and angle alpha Photopic and mesopic measurements of angle kappa and angle alpha at pre-operation and during follow-up are shown in Fig. 2. Longitudinally, no statistically significant changes were observed in photopic angle kappa (0.214 mm preoperatively vs. 0.211 mm at 3 months; Friedman test, P = 0.42), mesopic angle kappa (0.236 mm vs. 0.257 mm; P = 0.06), or angle alpha (0.387 mm vs. 0.372 mm; P = 0.60). At 3 months postoperatively, photopic angle kappa was significantly smaller than mesopic angle kappa (paired Wilcoxon, P = 0.001). Angle kappa values were below 0.3 mm in the majority of eyes, including 87 eyes under photopic and 74 eyes under mesopic conditions, while angle alpha values were below 0.5 mm in 86 eyes. Longitudinal changes in angle kappa (Photopic and Mesopic) and angle alpha from preoperative to postoperative follow-up. Violin plots depict the distribution of (A) photopic angle kappa, (B) mesopic angle kappa, and (C) angle alpha measured preoperatively and at 1 week, 1 month, and 3 months postoperatively. The width of each violin represents the data density. The central horizontal line denotes the median, and the upper and lower dashed lines indicate the first and third quartiles, respectively. Longitudinal comparisons revealed no significant differences (Friedman test: photopic angle kappa, P = 0.42; mesopic angle kappa, P = 0.06; angle alpha, P = 0.60) Correlations between angle metrics and postoperative visual outcomes As shown in Table 3, after adjustment for age, postoperative spherical equivalent, and pupil diameter, Spearman partial correlation analysis demonstrated no significant associations between postoperative photopic or mesopic angle kappa and uncorrected visual acuity at any distance, contrast threshold, objective optical quality parameters, or patient-reported photic phenomena (all P > 0.05). Table 3Partial correlation analysis between postoperative angle and visual outcomesParameterPhotopic angle kappaMesopic angle kappaAngle alphar ValueP Valuer ValueP Valuer ValueP ValueCDVA (logMAR)0.060.520.110.25-0.060.52UDVA (5 m)-0.100.280.020.81-0.220.021*UDVA (3 m)-0.080.400.050.60-0.220.023*UIVA (1 m)0.010.930.090.36-0.140.15UIVA (60 cm)-0.030.79-0.030.74-0.080.40UNVA (40 cm)0.010.90-0.070.50-0.100.30UNVA (33 cm)-0.040.68-0.060.55-0.160.10Contrast Threshold (%)-0.120.220.030.72-0.210.031*WFAs (µm)0.010.950.050.59-0.080.38HOAs (µm)0.090.330.120.23-0.040.68MTF Area Ratio (%)0.070.480.090.340.050.61Strehl ratio (%)0.070.500.080.44-0.010.92Glare score0.070.49-0.010.92-0.120.21Halo score-0.090.37-0.070.450.110.27Starburst score0.080.390.020.88-0.040.70Visual satisfaction score-0.030.77-0.140.150.080.44The partial correlation coefficient was analyzed by Spearman partial correlation analysis with age, postoperative spherical equivalent, photopic and mesopic pupil diameter as the controlling variables. *P < 0.05HOAs = high-order aberrations; MTF = modulation transfer function; WFA = wavefront aberrations Partial correlation analysis between postoperative angle and visual outcomes The partial correlation coefficient was analyzed by Spearman partial correlation analysis with age, postoperative spherical equivalent, photopic and mesopic pupil diameter as the controlling variables. *P < 0.05 HOAs = high-order aberrations; MTF = modulation transfer function; WFA = wavefront aberrations By contrast, angle alpha showed a weak but statistically significant negative correlation with UDVA at 5 m (r = − 0.22; 95% CI: −0.38 to − 0.05; P = 0.021) and 3 m (r = − 0.22; 95% CI: −0.38 to − 0.04; P = 0.023), and with contrast threshold (r = − 0.21; 95% CI − 0.38 to − 0.03; P = 0.031), indicating that angle alpha values were associated with slightly better UDVA (lower logMAR) and higher contrast sensitivity. Group comparisons by postoperative angle strata (3 months) At 3 months, patients were stratified by photopic angle kappa into A1 (< 0.3 mm; n = 87), A2 (0.3–< 0.5 mm; n = 21) and A3 (≥ 0.5 mm; n = 7). Mesopic angle kappa groups were defined similarly (B1, B2, B3; n = 74, 31, 10, respectively). Angle alpha was categorized into C1 (< 0.5 mm; n = 86) and C2 (≥ 0.5 mm; n = 29). Between-group comparisons are shown in Table 4. Table 4Comparison of different angle groups in visual outcomesParameterPhotopic angle kappaP ValueMesopic angle kappaP ValueAngle alphaP ValueGroup A1 (n = 87)Group A2 (n = 21)Group A3 (n = 7)Group B1 (n = 74)Group B2 (n = 31)Group B3 (n = 10)Group C1 (n = 86)Group C2 (n = 29)SEQ (D)-0.49 ± 0.63-0.66 ± 0.61-0.61 ± 0.670.49-0.46 ± 0.64-0.65 ± 0.66-0.66 ± 0.440.26-0.57 ± 0.63-0.41 ± 0.620.15CDVA (logMAR)0.01 ± 0.070.00 ± 0.090.01 ± 0.090.830.01 ± 0.080.03 ± 0.08-0.02 ± 0.060.210.01 ± 0.080.01 ± 0.070.76UDVA (5 m)0.16 ± 0.120.17 ± 0.130.16 ± 0.160.810.16 ± 0.110.19 ± 0.140.14 ± 0.080.390.17 ± 0.120.14 ± 0.110.08UDVA (3 m)0.15 ± 0.110.16 ± 0.140.16 ± 0.160.990.14 ± 0.110.17 ± 0.140.12 ± 0.090.440.16 ± 0.120.12 ± 0.110.14UIVA (1 m)0.13 ± 0.110.14 ± 0.100.14 ± 0.170.840.13 ± 0.120.15 ± 0.110.08 ± 0.080.240.13 ± 0.120.11 ± 0.080.52UIVA (60 cm)0.15 ± 0.110.15 ± 0.100.11 ± 0.150.510.16 ± 0.110.14 ± 0.100.10 ± 0.100.390.15 ± 0.120.15 ± 0.090.90UNVA (40 cm)0.25 ± 0.140.23 ± 0.120.20 ± 0.140.630.25 ± 0.140.23 ± 0.130.19 ± 0.120.390.24 ± 0.140.23 ± 0.120.80UNVA (33 cm)0.36 ± 0.180.32 ± 0.160.27 ± 0.210.420.36 ± 0.170.30 ± 0.170.36 ± 0.200.340.35 ± 0.180.33 ± 0.160.53Contrast Threshold (%)48.9 ± 25.947.4 ± 30.053.6 ± 33.00.8248.1 ± 27.250.0 ± 27.251.5 ± 26.00.8651.4 ± 27.641.6 ± 23.90.18WFAs (µm)0.96 ± 0.870.88 ± 0.320.80 ± 0.240.730.96 ± 0.920.91 ± 0.390.87 ± 0.180.490.98 ± 0.840.82 ± 0.490.07HOAs (µm)0.43 ± 0.670.34 ± 0.210.28 ± 0.090.780.42 ± 0.710.38 ± 0.290.37 ± 0.220.880.42 ± 0.660.35 ± 0.330.39MTF Area Ratio (%)28.8 ± 8.730.6 ± 14.830.3 ± 4.20.6029.3 ± 9.929.3 ± 11.228.8 ± 4.40.9429.1 ± 10.229.7 ± 9.20.46Strehl ratio (%)0.030 ± 0.0220.033 ± 0.0360.030 ± 0.0120.710.031 ± 0.0270.029 ± 0.0220.029 ± 0.0110.640.031 ± 0.0250.031 ± 0.0220.76Glare score0.30 ± 0.880.52 ± 1.370.00 ± 0.000.450.27 ± 0.760.39 ± 1.110.50 ± 1.580.910.30 ± 0.970.38 ± 0.940.54Halo score0.20 ± 0.530.29 ± 0.780.00 ± 0.000.570.20 ± 0.520.26 ± 0.730.00 ± 0.000.440.10 ± 0.340.38 ± 0.770.07Starburst score0.15 ± 0.620.38 ± 1.240.14 ± 0.380.920.15 ± 0.490.16 ± 0.900.60 ± 1.580.250.2 ± 0.810.17 ± 0.600.88Visual satisfaction score8.72 ± 1.569.10 ± 1.308.57 ± 0.790.228.95 ± 1.388.58 ± 1.548.20 ± 1.870.258.85 ± 1.338.59 ± 1.860.72Values are presented as mean ± standard deviation; Nonparametric tests (Kruskal–Wallis and Mann–Whitney U) were used for intergroup comparisons. P < 0.05 was considered statistically significant Comparison of different angle groups in visual outcomes Values are presented as mean ± standard deviation; Nonparametric tests (Kruskal–Wallis and Mann–Whitney U) were used for intergroup comparisons. P < 0.05 was considered statistically significant No statistically significant differences were observed across photopic or mesopic angle kappa strata in postoperative SEQ, uncorrected distance, intermediate, or near visual acuity, contrast threshold, wavefront aberrations, total HOAs, MTF area ratio, Strehl ratio, or patient-reported scores for glare, halo or starburst (minimum P ≥ 0.24). Similarly, comparisons between angle alpha groups revealed no significant differences in the primary objective or subjective outcomes. Notably, there was a non-significant trend toward better UDVA at 5 m (0.17 ± 0.12 vs. 0.14 ± 0.11 logMAR; P = 0.08) and contrast threshold (51.46 ± 27.6% vs. 41.6 ± 23.9%; P = 0.18) in the higher angle alpha group. Given the limited sample size in the highest-angle subgroups, these analyses were considered exploratory. Subjective visual outcomes Overall patient satisfaction was high, with a mean satisfaction score of 8.8 ± 1.5 (scale 0–10). The overall rate of spectacle independence was 80% (92/115). The overall incidence of patient-reported optical disturbances (glare, halos or starbursts) was 27%. Discussion In this prospective study, we evaluated the association between postoperative angle kappa, angle alpha and visual outcomes following implantation of a nondiffractive extended depth-of-focus (EDOF) intraocular lens. The vast majority of angle kappa and angle alpha values measured at 3 months postoperatively were within the physiological range, and the proportion of eyes with angle kappa and angle alpha ≥ 0.5 mm was low (photopic angle kappa: n = 7, 6.1%; mesopic angle kappa: n = 10, 8.7%; angle alpha: n = 29, 25.2%). These findings are consistent with previous literature reporting measurements of angle kappa and angle alpha using the OPD-SCAN III [20, 21]. Therefore, this study primarily reflects the impact of angular parameters within the physiological range on postoperative visual outcomes. After adjustment for relevant covariates, no consistent negative associations were observed between postoperative angle kappa and visual or optical outcomes, while a weak positive correlation between angle alpha and both UDVA and contrast threshold was noted. In this study, angle subgroups were defined primarily based on the physiological distribution of postoperative measurements. For comparative purposes, the 0.5 mm threshold—commonly cited in prior literature on diffractive IOLs—was also applied [7–10]. In the present cohort, eyes with higher values (angle kappa or angle alpha ≥ 0.5 mm) appeared to show visual outcomes and optical disturbance rates comparable to those with lower values. This observation, together with recent evidence suggesting that such cutoff values may be somewhat arbitrary [Fernández et al., 2025] [22], indicates that their clinical relevance may warrant cautious interpretation, particularly when applied across different IOL designs. In vitro optical simulations have demonstrated that the Vivity IOL maintains favorable imaging quality even with decentration of approximately 0.5 mm [12]; Furthermore, a laboratory study by Schmid et al. (2022) reported minimal impact on the modulation transfer function (MTF) of the Vivity IOL under a similar degree of decentration [13]. Our clinical findings are generally consistent with these laboratory observations, suggesting that this nondiffractive EDOF design may exhibit a certain degree of tolerance to clinically relevant positional deviations within the observed range. To contrast, reports of a marked decline in visual quality when angle kappa or angle alpha exceed 0.4–0.5 mm mainly involved cohorts implanted with diffractive multifocal or EDOF intraocular lens [4, 7, 8, 23–25], which is largely related to the concentric-ring optical design of diffractive IOLs. Furthermore, Kohnen et al. (2025) noted in a review that the existing literature on the relationship between angle kappa and postoperative visual quality or photic phenomena for multifocal IOLs remains inconsistent [26]. Such inconsistencies may arise from differences in study design, patient characteristics, the optical design of the MIOL used, and methods of measuring angle kappa. Therefore, these differences provide a reasonable context for our finding that angle kappa or angle alpha has no significant effect on Vivity performance. The relatively high tolerance of the AcrySof IQ Vivity IOL to angular decentration observed in the present study may be partly explained by its nondiffractive optical design. Previous optical studies have shown that this lens achieves an extended depth of focus through smooth, continuous modulation of surface curvature, rather than discrete diffractive steps, resulting in a more gradual redistribution of optical power across the optic [18]. From a theoretical perspective, such a profile may be less sensitive to moderate angular misalignment compared with conventional diffractive IOLs, as incident light is redistributed within a continuous focal range rather than being split into distinct diffraction orders. This optical characteristic may help explain why no clinically meaningful deterioration in visual performance was observed across the range of angle kappa and angle alpha in our cohort. It should be explicitly noted that this explanation represents a plausible optical hypothesis based on its design, rather than a mechanistic conclusion directly derived from the present study. An intriguing finding was the weak but statistically significant positive correlation between a larger angle alpha and better uncorrected distance visual acuity (UDVA) and contrast threshold. However, given the limited number of eyes with larger angle alpha values, this finding may represent a spurious association and should be interpreted with caution. Although a potential optical explanation could be considered—such as a relative redistribution of incident light toward more monofocal-like peripheral regions of the optic—this remains speculative and cannot be confirmed based on the present data. Alternatively, angle alpha may reflect underlying, unmeasured biometric characteristics (e.g., corneal asphericity) that could influence visual outcomes, and residual confounding cannot be excluded. Therefore, this observation should not be interpreted as evidence supporting the selection of larger angle alpha in clinical practice, but rather as an indication that visual performance appears stable across the range of values observed in this cohort. In the present study, angle kappa and angle alpha showed no significant longitudinal changes between preoperative and 3-month postoperative measurements (P > 0.05), indicating relative stability at the group level. While this suggests that preoperative values may approximate postoperative optical alignment, inter-individual variability was observed. Our analysis focused on postoperative measurements, as these more directly reflect the functional optical alignment underlying visual performance, particularly given prior evidence that angle kappa may decrease after cataract surgery [9, 10, 27].However, as longitudinal changes and intra-individual variability were not specifically analyzed, these findings should be interpreted with caution in the context of individual surgical planning. Further prospective studies are needed to clarify the clinical relevance of dynamic angle changes and the predictive value of preoperative measurements. This study has several limitations. First, as a single-center prospective study with a moderate sample size, the distribution of angle kappa and angle alpha was largely confined to physiological ranges, with only a small proportion of eyes exhibiting larger values. As a result, subgroup analyses involving higher-angle values are underpowered and should be interpreted with caution. In particular, comparisons presented in Table 4 may be affected by limited interindividual variability and statistical instability, potentially leading to inconclusive findings. Accordingly, subgroup analyses were considered exploratory, and their results should be interpreted in conjunction with the correlation analyses. Larger prospective studies including more eyes with higher angle values are warranted. Second, the 3-month follow-up period does not capture the long-term effects of IOL displacement on visual quality. Third, the use of only the OPD-Scan III for measurements limits device interchangeability. Finally, subjective visual disturbances were assessed using a non-validated questionnaire, which may introduce reporting bias. Conclusions In conclusion, this prospective observational study indicates that the AcrySof IQ Vivity non-diffractive EDOF IOL provides stable visual and optical outcomes within the commonly observed physiological range of postoperative angle kappa and angle alpha, without increasing the incidence of visual disturbances. The absence of negative correlations between these angular parameters and postoperative visual performance in the overall cohort supports this lens’ s suitability for the majority of patients encountered in routine clinical practice. However, a definitive assessment of its performance in eyes with very large angular offsets requires verification in future, specifically designed studies. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Not applicable. Abbreviations Intraocular lenses Multifocal intraocular lenses Extended depth of focus Corrected distance visual acuity Uncorrected distance visual acuity Uncorrected intermediate visual acuity Uncorrected near visual acuity Logarithm of the minimum angle of resolution Spherical equivalent Modulation transfer function Higher order aberrations Wavefront aberrations Author contributions All authors made a significant contribution to the work report. N.W. and X.W. conceived and designed the study. Y.Y. and B.Z. analyzed data. S.L. and Y.Z. acquired data, and drafted the manuscript. N.W. designed figures and wrote the paper. X.W. and B.Z. revised the manuscript critically. All authors reviewed and approved the final manuscript. Funding This research was funded by grants from the Science and Technology Innovation Joint Fund Project of the Fujian Provincial Department of Science and Technology (No. 2023Y9027, Yao Yihua) and the Natural Science Foundation of Fujian Province (No. 2023J01591, Wang Xiaohui and No.2025J0112, Yao Yihua). This work was also supported by the Fujian Provincial Clinical Medical Research Center of Eye Diseases and Optometry (YK-YJZX, Zhu Yihua). Data availability The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This research protocol received ethical approval from the Medical Research and Clinical Technology Application SubCommittee of the Ethics Committee of First Affiliated Hospital of Fujian Medical University (Approval No.: MTCA, FECFAH of FMU [2015]084 − 2), and all procedures strictly adhered to the ethical principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.